Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-01 |
2024-03 |
-0.06 |
-0.05 |
0.01 |
16.67% |
2024-02-20 |
2023-12 |
0 |
-0.04 |
N/A |
N/A |
2023-11-07 |
2023-09 |
0 |
-0.03 |
N/A |
N/A |
2023-08-09 |
2023-06 |
0 |
-0.02 |
N/A |
N/A |
2023-05-11 |
2023-03 |
0 |
-0.06 |
N/A |
N/A |
2023-03-09 |
2022-12 |
0 |
-0.07 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2020-11-17 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2020-03-18 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2018-06-27 |
Janney Montgomery Scott |
Downgrade |
Buy |
Neutral |
2018-06-26 |
SunTrust Robinson Humphrey |
Downgrade |
Buy |
Hold |
2018-05-01 |
Janney Montgomery Scott |
Upgrade |
|
Buy |
2018-02-12 |
BTIG |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-03-25 |
DHINGRA ANKUR |
Chief Financial Officer |
0.00 |
Purchase |
2023-03-05 |
DUGGAN ROBERT WILLIAM |
Chief Executive Officer |
552.35M |
Purchase |
2020-11-29 |
POWELL DAVID JONATHAN |
Officer |
0.00 |
Sale |
2023-10-12 |
SONI MANMEET SINGH |
Chief Operating Officer |
2.98M |
Purchase |
2023-03-06 |
XIA YU |
Director |
0.00 |
Purchase |
2024-03-26 |
ZANGANEH MAHKAM |
Chief Executive Officer |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
8.76M |
21.99M |
1.26% |
2023-06-29 |
Baker Brothers Advisors, LLC |
6.30M |
15.82M |
0.90% |
2023-06-29 |
Vanguard Group Inc |
6.10M |
15.31M |
0.87% |
2023-06-29 |
Geode Capital Management, LLC |
2.68M |
6.73M |
0.38% |
2023-06-29 |
State Street Corporation |
2.25M |
5.66M |
0.32% |
2023-06-29 |
Northern Trust Corporation |
1.03M |
2.59M |
0.15% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.66M |
9.19M |
0.52% |
2023-08-30 |
iShares Russell 2000 ETF |
2.66M |
4.31M |
0.38% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.42M |
3.57M |
0.20% |
2023-07-30 |
Fidelity Small Cap Index Fund |
1.01M |
2.13M |
0.15% |
2023-08-30 |
iShares Russell 2000 Growth ETF |
1.00M |
1.63M |
0.14% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
771.85K |
1.25M |
0.11% |